# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $4 price t...
Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular gl...
Wedbush analyst David Nierengarten downgrades Ikena Oncology (NASDAQ:IKNA) from Outperform to Neutral and lowers the price t...
HC Wainwright & Co. analyst Andres Maldonado maintains Ikena Oncology (NASDAQ:IKNA) with a Buy and lowers the price targ...